Ubrogepant

FDA APPROVAL DATE: 12/23/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

BCRP and/or P-gp only inhibitors, CYP3A4 inhibitors, CYP3A4 inducers, Ciprofloxacin, Clarithromycin, Cyclosporine, Fluconazole, Fluvoxamine, Grapefruit Juice, Itraconazole, Ketoconazole, Phenytoin, Rifampin, St John's Wort, Verapamil


There are no adequate data on the developmental risk associated with use in pregnant women.
NOTE

Ubrogepant is not indicated for the preventive treatment of migraine.

Avoid use in patients with end-stage renal disease.

Our database has 11 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top